SCHEMBL4962272

SCHEMBL4962272

N#Cc1cnc2c(Br)cc(NCc3cn(CCN)nn3)cc2c1Nc1ccc(F)c(Cl)c1

nearest known ligand 0.88

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 20/20 0.88
CAMK2B Q13554 1/20 0.82
CAMK2G Q13555 1/20 0.82
CAMK2D Q13557 1/20 0.82
CAMK2A Q9UQM7 1/20 0.82
MAPKAPK2 P49137 2/20 0.73
LCK P06239 1/20 0.73
CYP3A4 P08684 1/20 0.73
RPS6KB1 P23443 1/20 0.73
MAPK8 P45983 1/20 0.73
EGFR P00533 1/20 0.68
SRC P12931 1/20 0.68
MAPK14 Q16539 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27728272 0.93 MAP3K8 (0.84) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL27728115 0.92 MAP3K8 (0.83) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL27707451 0.92 MAP3K8 (0.81) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL4963272 0.91 MAP3K8 (0.88) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL27707344 0.91 MAP3K8 (0.92) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL27707379 0.91 MAP3K8 (0.80) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL4961915 0.91 MAP3K8 (0.89) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL27728051 0.91 MAP3K8 (0.81) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL4963350 0.91 MAP3K8 (0.89) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A
SCHEMBL4961764 0.90 MAP3K8 (0.83) MAP3K8CAMK2BCAMK2GCAMK2DCAMK2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101223143-A 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same WYETH CORP (US) 2008-07-16 CN disclosed
EP-1888529-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-02-20 EP disclosed
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed
WO-2006124692-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 MAP3K8 84/4885CAMK2B 159/4885CAMK2G 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.